{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:26:37Z","timestamp":1790040397355,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2002,7,1]]},"DOI":"10.1038\/sj.bmt.1703602","type":"journal-article","created":{"date-parts":[[2002,9,3]],"date-time":"2002-09-03T18:26:31Z","timestamp":1031077591000},"page":"23-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease"],"prefix":"10.1038","volume":"30","author":[{"given":"AD","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SM","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Sickles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PA","family":"Mangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DL","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SJ","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DE","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Nasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AM","family":"Gewirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EA","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,7,16]]},"reference":[{"key":"BF1703602_CR1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","volume":"341","author":"B Lowenberg","year":"1999","unstructured":"Lowenberg B, Downing J, Burnett A . Acute myeloid leukemia New Engl J Med 1999 341: 1051 1062","journal-title":"New Engl J Med"},{"key":"BF1703602_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1046\/j.1365-2141.1999.01629.x","volume":"106","author":"D Webb","year":"1999","unstructured":"Webb D . Management of relapsed acute myeloid leukaemia Br J Haematol 1999 106: 851 859","journal-title":"Br J Haematol"},{"key":"BF1703602_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/1096-8652(200007)64:3<232::AID-AJH20>3.0.CO;2-#","volume":"64","author":"V Levy","year":"2000","unstructured":"Levy V, Marjanovic Z, Vekhoff A et al. Relapse after autologous hematopoietic stem cell transplantation in acute myeloid leukemia, a single center experience over 13 years Am J Hematol 2000 64: 232 233","journal-title":"Am J Hematol"},{"key":"BF1703602_CR4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","volume":"67","author":"P Dinndorf","year":"1986","unstructured":"Dinndorf P, Andrews R, Benjamin D et al. Expression of normal myeloid\u2013associated antigens by acute leukemia cells Blood 1986 67: 1048 1053","journal-title":"Blood"},{"key":"BF1703602_CR5","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","volume":"93","author":"E Sievers","year":"1999","unstructured":"Sievers E, Appelbaum F, Speilberger R et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 1999 93: 3678 3684","journal-title":"Blood"},{"key":"BF1703602_CR6","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","volume":"19","author":"E Sievers","year":"2001","unstructured":"Sievers E, Larson R, Stadtmauer E et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 2001 19: 3244 3254","journal-title":"J Clin Oncol"},{"key":"BF1703602_CR7","first-page":"3599","volume":"92","author":"E Carreras","year":"1998","unstructured":"Carreras E, Bertz H, Arcese W et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation Blood 1998 92: 3599 3604","journal-title":"Blood"},{"key":"BF1703602_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00001622-200003000-00001","volume":"12","author":"S Bearman","year":"2000","unstructured":"Bearman S . Veno-occlusive disease of the liver Curr Opin Oncol 2000 12: 103 109","journal-title":"Curr Opin Oncol"},{"key":"BF1703602_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1046\/j.1365-2141.1999.01680.x","volume":"107","author":"P Richardson","year":"1999","unstructured":"Richardson P, Guinan E . The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches Br J Haematol 1999 107: 485 493","journal-title":"Br J Haematol"},{"key":"BF1703602_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1034\/j.1600-0609.2000.9r200.x","volume":"64","author":"E Carreras","year":"2000","unstructured":"Carreras E . Veno-occlusive disease of the liver after hemopoietic cell transplantation Eur J Haematol 2000 64: 281 291","journal-title":"Eur J Haematol"},{"key":"BF1703602_CR11","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","volume":"89","author":"S Bearman","year":"1997","unstructured":"Bearman S, Lee J, Baron A et al. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients Blood 1997 89: 1501 1506","journal-title":"Blood"},{"key":"BF1703602_CR12","first-page":"142","volume":"4","author":"P Richardson","year":"1998","unstructured":"Richardson P, Elias D, Krishnan A et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in efficacy without significant toxicity in a high risk population Blood 1998 4: 142 150","journal-title":"Blood"},{"key":"BF1703602_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/00313029400169601","volume":"26","author":"KL Barclay","year":"1994","unstructured":"Barclay KL, Yeong ML . Actinomycin D associated hepatic veno-occlusive disease \u2014 a report of 2 cases Pathology 1994 26: 257 260","journal-title":"Pathology"},{"key":"BF1703602_CR14","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2435::AID-CNCR21>3.0.CO;2-R","volume":"79","author":"JA Ortega","year":"1997","unstructured":"Ortega JA, Donaldson SS, Ivy SP et al. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma Cancer 1997 79: 2435 2439","journal-title":"Cancer"},{"key":"BF1703602_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7326\/0003-4819-96-1-58","volume":"96","author":"RA Gill","year":"1982","unstructured":"Gill RA, Onstad GR, Cardamone JM et al. Hepatic veno-occlusive disease caused by 6-thioguanine Ann Intern Med 1982 96: 58 60","journal-title":"Ann Intern Med"},{"key":"BF1703602_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s002770000239","volume":"80","author":"P Neumeister","year":"2001","unstructured":"Neumeister P, Eibl M, Zinke-Cerwenka W et al. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate Ann Hematol 2001 80: 119 120","journal-title":"Ann Hematol"},{"key":"BF1703602_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"G McDonald","year":"1993","unstructured":"McDonald G, Hinds M, Fisher L et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 118: 255 267","journal-title":"Ann Intern Med"},{"key":"BF1703602_CR18","first-page":"206b","volume":"96","author":"E Sievers","year":"2000","unstructured":"Sievers E, Larson R, Estey E et al. Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676): relationship to hematopoietic stem cell transplantation Blood 2000 96: 206b","journal-title":"Blood"},{"key":"BF1703602_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","volume":"92","author":"F Giles","year":"2001","unstructured":"Giles F, Kantarjian H, Kornblau S et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation Cancer 2001 92: 406 413","journal-title":"Cancer"},{"key":"BF1703602_CR20","first-page":"41","volume":"14 (9 Suppl. 8)","author":"JW Smith","year":"2000","unstructured":"Smith JW . Tolerability and side-effect profile of rhIL-11 Oncology 2000 14 (9 Suppl. 8): 41 47","journal-title":"Oncology"},{"key":"BF1703602_CR21","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood.V87.9.3615.bloodjournal8793615","volume":"87","author":"MS Gordon","year":"1996","unstructured":"Gordon MS, McCaskill-Stevens WJ, Battiato LA et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy Blood 1996 87: 3615 3624","journal-title":"Blood"},{"key":"BF1703602_CR22","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/sj.bmt.1701506","volume":"22","author":"S Hasegawa","year":"1998","unstructured":"Hasegawa S, Horibe K, Kawabe T et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors Bone Marrow Transplant 1998 22: 1191 1197","journal-title":"Bone Marrow Transplant"},{"key":"BF1703602_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0002-9378(97)70155-8","volume":"177","author":"J Gilles","year":"1997","unstructured":"Gilles J, Divon M, Bentolila E et al. Immunophenotypic characterization of human fetal liver hematopoietic stem cells during the midtrimester of gestation Am J Obstet Gynecol 1997 177: 619 625","journal-title":"Am J Obstet Gynecol"},{"key":"BF1703602_CR24","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/hep.1840210606","volume":"21","author":"K Blakolmer","year":"1995","unstructured":"Blakolmer K, Jaskiewicz K, Dunsford H et al. Hematopoietic stem cell markers are expressed by ductal plate and bile duct cells in developing human liver Hepatology 1995 21: 1510 1516","journal-title":"Hepatology"},{"key":"BF1703602_CR25","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1182\/blood.V83.11.3170.3170","volume":"83","author":"M Muench","year":"1994","unstructured":"Muench M, Cupp J, Polakoff J et al. Expression of CD33, CD38, and HLA-DR on CD34+ human fetal liver progenitors with a high proliferative potential Blood 1994 83: 3170 3181","journal-title":"Blood"},{"key":"BF1703602_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/icb.1993.63","volume":"71","author":"E Favaloro","year":"1993","unstructured":"Favaloro E . Differential expression of surface antigens on activated endothelium Immunol Cell Biol 1993 71: 571 581","journal-title":"Immunol Cell Biol"},{"key":"BF1703602_CR27","first-page":"2","volume":"36","author":"F Applebaum","year":"1999","unstructured":"Applebaum F . Antibody-targeted therapy for myeloid leukemia Sem Hematol 1999 36: (Suppl. 6) 2 8","journal-title":"Sem Hematol"},{"key":"BF1703602_CR28","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/1097-0142(19940201)73:3+<1049::AID-CNCR2820731344>3.0.CO;2-1","volume":"73","author":"P Caron","year":"1994","unstructured":"Caron P, Schwartz M, Sung Co M et al. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia Cancer 1994 73: (Suppl.) 1049 1056","journal-title":"Cancer"},{"key":"BF1703602_CR29","first-page":"5908s","volume":"55","author":"J Jurcic","year":"1995","unstructured":"Jurcic J, Caron P, Nikula T et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias Cancer Res 1995 55: (Suppl.) 5908s 5910s","journal-title":"Cancer Res"},{"key":"BF1703602_CR30","first-page":"124a","volume":"98","author":"EA Stadtmauer","year":"2001","unstructured":"Stadtmauer EA, Larson R, Sievers E et al. Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676) Blood 2001 98: 124a","journal-title":"Blood"},{"key":"BF1703602_CR31","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1126\/science.3240341","volume":"240","author":"N Zein","year":"1988","unstructured":"Zein N, Sinha AM, McGahren WJ et al. Calicheamicin \u03b3I1: an antitumor antibiotic that cleaves double-stranded DNA site specifically Science 1988 240: 1198 1201","journal-title":"Science"},{"key":"BF1703602_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0037-1963(01)90153-2","volume":"38","author":"RA Larson","year":"2001","unstructured":"Larson RA . Current use and future development of gemtuzumab ozogamicin Semin Hematol 2001 38: (Suppl. 6) 24 31","journal-title":"Semin Hematol"},{"key":"BF1703602_CR33","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1023\/A:1008349300781","volume":"11","author":"AM Gillespie","year":"2000","unstructured":"Gillespie AM, Broadhead TJ, Chan SY et al. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer Ann Oncol 2000 11: 735 741","journal-title":"Ann Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703602","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:33:44Z","timestamp":1648078424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,7,1]]}},"alternative-id":["BF1703602"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703602","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7,1]]},"assertion":[{"value":"30 November 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}